ArticleBMC surgery2026
Endoscopic variceal ligation versus sclerotherapy in patients with gastric variceal bleed.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe purpose of this study was to evaluate the clinical outcomes and determinants of rebleeding in patients with gastric variceal bleeding undergoing Endoscopic Variceal Ligation (EVL) and Sclerotherapy (EST).
methodsA retrospective cohort analysis was conducted on patients with gastric variceal bleeding treated with EVL or EST between January 2018 and January 2020. Data were collected from hospital records, including patient demographics, clinical presentation, laboratory results, endoscopic findings, and treatment outcomes. Statistical analysis was performed to compare the efficacy, complications, and rebleeding rates between the two treatment groups.
resultsA total of 70 patients were included, with 35 patients in each treatment group (EVL and EST). The baseline characteristics, including etiology of cirrhosis and clinical presentation, were comparable between the groups. Both EVL and EST showed 80% efficacy in controlling initial bleeding. However, long-term rebleeding rates were significantly higher in the EST group (34.3%) compared to the EVL group (11.4%). Factors such as lower RBC and Hb levels, higher bilirubin and AST levels, and prolonged PT and INR were significantly associated with rebleeding in both groups.
conclusionsBoth EVL and EST are effective in managing acute gastric variceal bleeding. However, EVL may offer better long-term outcomes in terms of rebleeding rates.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.